Literature DB >> 7979550

Effects of oral thalidomide on rat liver and skin microsomal P450 isozyme activities and on urinary porphyrin excretion: interaction with oral hexachlorobenzene.

D Tsambaos1, K Bolsen, S Georgiou, A Monastirli, G Goerz.   

Abstract

Adult female Wistar rats (n = 48) divided into four groups of 12 were treated orally with 3 mg/kg per day thalidomide, a 0.05% hexachlorobenzene (HCB)--containing diet, with both drugs together and with the vehicles (controls) over periods of 10 and 60 days. The protein and P450 contents and the activities of aminopyrine-N-demethylase (ADM) and 7-ethoxyresorufin-O-deethylase (7-ERO-D) were determined in the liver microsomes. The activity of 7-ERO-D was also determined in the skin microsomes and total porphyrins were measured in the urine of the animals. Thalidomide increased the hepatic P450 content, caused distinct changes in the activities of the hepatic and cutaneous microsomal isozymes, modified their induction by HCB and inhibited the porphyrogenic activity of HCB. These findings indicate an interaction between thalidomide and HCB with regard to their effects on the P450 isozymes and the metabolism of porphyrins.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7979550     DOI: 10.1007/BF00402227

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  23 in total

1.  THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE.

Authors:  T OMURA; R SATO
Journal:  J Biol Chem       Date:  1964-07       Impact factor: 5.157

2.  Mixed type hepatic microsomal enzyme induction by hexachlorobenzene.

Authors:  M D Stonard
Journal:  Biochem Pharmacol       Date:  1975-11-01       Impact factor: 5.858

3.  Thalidomide in hyperalgic pharyngeal ulceration of AIDS.

Authors:  I Gorin; B Vilette; P Gehanno; J P Escande
Journal:  Lancet       Date:  1990-06-02       Impact factor: 79.321

4.  [Long time HCB exposition of rats: influence on the porphyrin excretion in the urine and on the cytochrome P-450 in the liver (author's transl)].

Authors:  G Goerz; T Krieg; K Bolsen; R Lissner
Journal:  Arch Dermatol Res       Date:  1977-08-22       Impact factor: 3.017

5.  Results of a double blind study of the influence of thalidomide on the lepra reaction.

Authors:  J Sheskin; J Convit
Journal:  Int J Lepr Other Mycobact Dis       Date:  1969 Apr-Jun

6.  A new animal model for the study of cutaneous drug-metabolizing enzymes.

Authors:  G Goerz; H Berger; D Tsambaos
Journal:  Arch Dermatol Res       Date:  1981       Impact factor: 3.017

7.  Cutaneous cytochrome P-450 activity during hexachlorobenzene-induced experimental porphyria in rats.

Authors:  G Goerz; W Vizethum; D Tsambaos
Journal:  Arch Dermatol Res       Date:  1979-05-29       Impact factor: 3.017

8.  Influence of chloroquine on the porphyrin metabolism.

Authors:  G Goerz; K Bolsen; H Merk
Journal:  Arch Dermatol Res       Date:  1985       Impact factor: 3.017

9.  Evidence for the intercalation of thalidomide into DNA: clue to the molecular mechanism of thalidomide teratogenicity?

Authors:  H P Koch; M J Czejka
Journal:  Z Naturforsch C J Biosci       Date:  1986 Nov-Dec

10.  Thalidomide treatment of prurigo nodularis.

Authors:  R K Winkelmann; S M Connolly; J A Doyle; A Padilha-Goncalves
Journal:  Acta Derm Venereol       Date:  1984       Impact factor: 4.437

View more
  2 in total

1.  Thalidomide increases human hepatic cytochrome P450 3A enzymes by direct activation of the pregnane X receptor.

Authors:  Norie Murayama; Rinie van Beuningen; Hiroshi Suemizu; Christiane Guguen Guillouzo; Norio Shibata; Kanako Yajima; Masahiro Utoh; Makiko Shimizu; Christophe Chesné; Masato Nakamura; F Peter Guengerich; René Houtman; Hiroshi Yamazaki
Journal:  Chem Res Toxicol       Date:  2014-02-05       Impact factor: 3.739

Review 2.  Clinical pharmacokinetics of thalidomide.

Authors:  Steve K Teo; Wayne A Colburn; William G Tracewell; Karin A Kook; David I Stirling; Markian S Jaworsky; Michael A Scheffler; Steve D Thomas; Oscar L Laskin
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 5.577

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.